|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TERT promoter mutations were most frequently present in bladder cancer (68.6%), followed by central nervous system tumors (28.7%), thyroid cancer (15.4%), prostate cancer (9.3%), endometrial carcinoma (3.7%), rhabdomyosarcoma (1.4%), colorectal cancer (1%), epithelial ovarian carcinoma (0.7%) and breast cancer (0.7%).
|
31669704 |
2020 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Samples were analyzed for TERT promoter mutations with Safe-SeqS, a sequencing error-reduction technology, and sequenced using a targeted panel of the 10 most commonly mutated genes in bladder cancer on the Illumina MiSeq platform.
|
30447301 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy-two percent of pT1 and 63% of muscle-invasive bladder tumors harbored TERT promoter mutations with g.1295228C>T alteration being the most common in all groups.
|
31028363 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations occur in the majority of glioblastoma, bladder cancer (BC), and other malignancies while the ETS family transcription factors GABPA and its partner GABPB1 activate the mutant TERT promoter and telomerase in these tumors.
|
31802036 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
|
30350309 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
|
30528938 |
2019 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Caution is warranted in exploring TERT promoter mutation status as a screening or adjunct diagnostic test for bladder cancer.
|
26679899 |
2016 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted from urine cell pellets and PCR used to amplify the regions of the TERT promoter and coding regions of FGFR3, PIK3CA, TP53, HRAS, KDM6A and RXRA which are frequently mutated in bladder cancer.
|
26901314 |
2016 |
|
LOC110806263
|
0.100 |
Biomarker
|
disease |
BEFREE |
TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
|
25657201 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer.
|
25809917 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.
|
26143634 |
2015 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter C228T and C250T mutations occur in various malignancies including bladder cancer (BC) and may serve as urinary tumor markers.
|
25474136 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic variants altering the TERT promoter were found in 69% of tumors but were not correlated with alterations in other bladder cancer genes.
|
25225064 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because the mutant TERT promoter in urine DNA was recently tested as a marker for BC, it is important to ascertain whether these mutations are truly absent in RCCs.
|
24742867 |
2014 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations occur in both papillary and flat lesions, are the most frequent genetic alterations identified to date in noninvasive precursor lesions of the bladder, are detectable in urine, and seem to be strongly associated with bladder cancer recurrence.
|
24121487 |
2013 |
|
LOC110806263
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The TERT promoter mutations are the most common somatic lesions in bladder cancer with clinical implications.
|
24101484 |
2013 |